Jasper Therapeutics, Inc. filed a Form 8-K on November 4, 2026, disclosing that it effected a 1-for-30 reverse stock split of its voting common stock, with the split becoming effective at 12:01 a.m. Eastern Time on November 6, 2026.

Key Highlights

  • Reverse split ratio: The Board set the ratio at 1-for-30, within the stockholder-approved range of 1-for-15 to 1-for-35.
  • Shares outstanding reduced: Shares of common stock issued and outstanding will fall from approximately 33.3 million to approximately 1.1 million, subject to fractional share adjustments.
  • Authorized shares unchanged: The number of authorized shares of common stock remains at 490,000,000 and will not be reduced.
  • Effective date: The reverse stock split became effective at 12:01 a.m. Eastern Time on November 6, 2026, with trading on an adjusted basis expected to begin at market open that day.
  • Fractional shares: No fractional shares will be issued; cash will be paid equal to the fractional amount multiplied by the closing sales price on November 5, 2026.
  • Trading symbol and CUSIP: The trading symbol remains "JSPR" and the new CUSIP number is 471871301.
  • Warrants and options adjusted: Outstanding warrants and stock options will be proportionately adjusted, including adjustments to their respective exercise prices.

Jasper Therapeutics Files Certificate of Amendment for 1-for-30 Reverse Split Effective November 6, 2026

According to the filing, Jasper Therapeutics, Inc. (NASDAQ:JSPR) filed a Certificate of Third Amendment to its Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on November 2, 2026, to effect the reverse stock split. The Board of Directors approved and authorized the filing on October 23, 2026, selecting a 1-for-30 ratio from within the range approved by stockholders at a special meeting held on September 30, 2026. That stockholder vote had authorized the Board to effect the split at any ratio between 1-for-15 and 1-for-35, at any time on or before December 31, 2026, as described in the company's definitive proxy statement filed with the SEC on September 4, 2026.

As a result of the reverse stock split, the filing states that every thirty shares of pre-split common stock will be combined into one share of post-split common stock, with no change in par value per share, which remains $0.0001. The company disclosed that proportionate voting rights and other rights of holders of common stock will not be affected, other than as a result of the payment of cash in lieu of fractional shares. The filing noted that the reverse stock split will affect all holders of common stock uniformly and will not affect any stockholder's percentage ownership interest, except for de minimis changes resulting from fractional share treatment.

The filing further disclosed that stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take any action, as their accounts will be automatically adjusted. Stockholders of record will receive information from Continental Stock Transfer and Trust Company regarding their stock ownership and any applicable cash payments in lieu of fractional shares. Equity incentive plan share pools will also be proportionately adjusted for the reverse stock split ratio, the filing noted.

What Was Disclosed

Jasper Therapeutics disclosed a 1-for-30 reverse stock split of its voting common stock, effective November 6, 2026, reducing shares outstanding from approximately 33.3 million to approximately 1.1 million, while authorized shares remain at 490,000,000 and the trading symbol remains JSPR.